Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.17
-0.2000-0.28%
Post-market: 71.15-0.0200-0.03%19:30 EDT
Volume:313.32K
Turnover:22.29M
Market Cap:3.85B
PE:6.41
High:71.44
Open:71.17
Low:70.93
Close:71.37
52wk High:74.59
52wk Low:56.44
Shares:54.15M
Float Shares:54.15M
Volume Ratio:0.34
T/O Rate:0.58%
Dividend:0.80
Dividend Rate:1.12%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.38
PE(LYR):23.26

Loading ...

Twist Bioscience Corporation - to Provide Antibody Characterization Data Services for Lilly Tunelab

THOMSON REUTERS
·
Sep 16

Circle Pharma: Financing Led by Column Group, Participation from Nextech Invest, Ra Capital Management, Strategic Investment from Eli Lilly and Co

THOMSON REUTERS
·
Sep 16

Estee Lauder Cos. Cl a Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 16

UnitedHealth Group Announces Earnings Release Date

THOMSON REUTERS
·
Sep 16

Health Rounds: New Dye for MRI Exams Detects Lung Cancer Earlier

Reuters
·
Sep 16

Thatch Raises $108 Million at $1 Billion Valuation

Reuters
·
Sep 16

Thatch: Funding & Participation from the General Partnership, General Catalyst, Andreessen Horowitz, ADP Ventures, Eli Lilly & Others

THOMSON REUTERS
·
Sep 16

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU
·
Sep 16

LIVE Markets-from Ozempic Face to K-Beauty Factories: the Next Beauty Bet

Reuters
·
Sep 15

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate

TIPRANKS
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15

Abbvie Exec Says Will Present Late-Stage Data for Blood Cancer Drug Etentamig at International Myeloma Society Meeting Later in September - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Existing Portfolio Provides 'Clear Line of Sight' to Very Strong Growth Well into Next Decade - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Apogee Fits 'Very Nicely' with Its Business Development Approach - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Plans to Start Enrolling Apogee's Zumilokibart This Year, Targets Launch in Early 2030 - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Tavapadon U.S. Launch Expected to Have 'Slower Burn' Due to Timing of Medicare Reimbursement - Conf Call

THOMSON REUTERS
·
Sep 15

Why One of the Last Eli Lilly Holdouts Just Upgraded the Stock to Buy

Dow Jones
·
Sep 15

Dow's Nearly 300-Point Fall Led by Losses in Johnson & Johnson, Nike Stocks

Dow Jones
·
Sep 15